By Dave Sebastian

Eli Lilly & Co. and Amgen Inc. said they are collaborating on making Lilly's potential Covid-19 antibody therapies, in an effort to boost supply if the treatment is approved.

The two companies expect to produce millions of doses next year, said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories.

Write to Dave Sebastian at dave.sebastian@wsj.com